

Supplemental Table 1: Dose Escalation Schedule

Dose Level	Minimum Number of Subjects	Efatutazone Dose	Paclitaxel Dose
-1 ^a	3	0.10 mg every 12 hours	135 mg/m ² IV over 3 hours once every 3 weeks
1a ^b	3	0.15 mg every 12 hours	135 mg/m ² IV over 3 hours once every 3 weeks
1b ^b		0.15 mg every 12 hours	175 mg/m ² IV over 3 hours once every 3 weeks
2	3	0.30 mg every 12 hours	175 mg/m ² IV over 3 hours once every 3 weeks
3	3	0.50 mg every 12 hours	175 mg/m ² IV over 3 hours once every 3 weeks

Abbreviations: IV = intravenous; DLT = dose-limiting toxicity; BID = twice daily; RP2D = recommended Phase dose.

- a: Dose Level -1 is included in case unexpected DLTs occur during treatment on Dose Level 1 (starting dose level).
- b: Subjects completing 1 cycle of treatment at Dose Level 1a were treated at Dose Level 1b in the second treatment cycle. The only difference between Dose Levels 1a and 1b was the dose of paclitaxel. Three patients received only dose level 1a and four received dose 1b.

Supplemental Table 2: Instances of Edema and/or Swelling

Indication	Efatutazone (BID) Dose (mg)	CTCAE Grade
FACE EDEMA/SWELLING		
Subject 03	0.15	2
Subject 05	0.15	2
Subject 08	0.30	1
LOCALIZED EDEMA		
Subject 09	0.30	3
JOINT SWELLING		
Subject 08	0.30	1
PERIPHERAL EDEMA		
Subject 06	0.15	2
Subject 09*	0.30	1
Subject 09*	0.30	1
Subject 09*	0.30	2
Subject 05	0.15	1
Subject 13	0.30	3
Subject 15	0.30	1
Subject 16	0.30	1

*: Subject 09 had 3 events of peripheral edema.

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events

